Cardiology Month in Review: July 2021

July's month in review features stories related to EMPEROR-Preserved meeting primary endpoint, a Q&A with Javed Butler, MD, on heart failure prevention, comparing ACEs vs ARBs, and more. Check back around the end of each month for the next Cardiology Month in Review.

Editor's note: Clicking on the center of a slide will redirect users to the content associated with that slide.

Top Stories of July 2021:

  1. EMPEROR-Preserved Meets Primary Endpoint, Cements Empagliflozin's Potential in HFpEF
    While many have speculated about the effect of SGLT2 inhibitors in HFpEF for years, EMPEROR-Preserved provides the first evidence from a phase 3 RCT of the safety and efficacy of empagliflozin for use in patients with heart failure across the spectrum of ejection fraction.
  2. Q&A on Heart Failure Prevention, with Javed Butler, MD
    Practical Cardiology sat down with Javed Butler, MD, following his presentation at ASPC 2021 to discuss how recent advances have impacted prevention of heart failure and how he views the role of primary care/internal medicine in primary prevention.
  3. ACEs & ARBs Similar in Event Prevention, But ARBs Have Favorable Safety Profile
    A retrospective cohort study with data from nearly 4 million patients with hypertension from the US, Germany, and South Korea found ACEs and ARBs provide similar efficacy for prevention of cardiovascular events, but ACEs were associated with a greater risk of adverse events.
  4. Renewed Hope for Inclisiran as Novartis Announces Complete Response Resubmission to US FDA
    Novartis announced the Complete Response resubmission for inclisiran in a statement on July 6, 2021.
  5. Diagnosis of Cardiac Non-Compaction in Athletes, with Paul D. Thompson, MD
    In his latest column, Dr. Paul Thompson offers perspective on the diagnosis and potential overdiagnosis of non-compaction cardiomyopathy in athletes.